A S Vickram, Shofia Saghya Infant, Saravanan A, Sivakumar Vidhya Lakshmi, Thamarai Packiyam, Sivasubramanian Manikandan, Chopra Shivani, Chopra Hitesh
Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India.
Department of Biosciences, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai - 602105, Tamil Nadu, India.
EXCLI J. 2024 Oct 29;23:1303-1326. doi: 10.17179/excli2024-7783. eCollection 2024.
The emergence of checkpoint inhibitors targeting the PD-1/PD-L1 axis marks a paradigm shift in cancer therapy, offering a novel avenue for enhancing patient outcomes. This review examines the structural and functional dynamics of PD-1 and PD-L1 while exploring the clinical implications of current PD-1/PD-L1 monoclonal antibodies. Highlighting recent advancements, this paper delves into the promising results from combination therapies that present a multifaceted attack on tumor progression. Despite the success observed across various cancer types, challenges such as immune resistance remain. Future considerations are discussed with an emphasis on the need for further clinical studies, aiming to refine and broaden the curative potential of PD-1/PD-L1 inhibitors in oncology. This review postulates that ongoing research and innovative approaches could significantly enhance cancer care, making immunotherapy an even more central strategy in the fight against cancer. See also the graphical abstract(Fig. 1).
靶向PD-1/PD-L1轴的检查点抑制剂的出现标志着癌症治疗的范式转变，为改善患者预后提供了一条新途径。本综述研究了PD-1和PD-L1的结构和功能动态，同时探讨了当前PD-1/PD-L1单克隆抗体的临床意义。本文突出了近期的进展，深入探讨了联合疗法取得的有前景的结果，这些联合疗法对肿瘤进展进行了多方面的攻击。尽管在各种癌症类型中都观察到了成功，但免疫抵抗等挑战仍然存在。讨论了未来的考虑因素，重点强调了进一步开展临床研究的必要性，旨在完善和扩大PD-1/PD-L1抑制剂在肿瘤学中的治愈潜力。本综述推测，正在进行的研究和创新方法可能会显著改善癌症治疗，使免疫疗法在对抗癌症的斗争中成为更加核心的策略。另见图1的图形摘要。
